Enliven Therapeutics, Inc.
ELVN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $102 | $119 | $102 | $124 |
| Short-Term Investments | $376 | $371 | $188 | $189 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $5 | $5 | $5 |
| Total Curr. Assets | $483 | $496 | $294 | $318 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $7 | $7 | $7 | $7 |
| Total NC Assets | $8 | $8 | $8 | $8 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $491 | $504 | $303 | $326 |
| Liabilities | – | – | – | – |
| Payables | $1 | $2 | $2 | $1 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $13 | $12 | $12 | $15 |
| Total Curr. Liab. | $15 | $15 | $14 | $16 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $0 | $0 |
| Total Liabilities | $15 | $15 | $14 | $16 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$317 | -$297 | -$272 | -$243 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $793 | $786 | $560 | $553 |
| Total Equity | $476 | $488 | $288 | $310 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $491 | $504 | $303 | $326 |
| Net Debt | -$101 | -$119 | -$101 | -$124 |